
Tratamiento de infección por virus hepatitis C con nuevos antivirales en pediatría: a propósito de un caso
Author(s) -
Erika M Selzer Soria,
Ivone Malla
Publication year - 2021
Publication title -
archivos argentinos de pediatría
Language(s) - Spanish
Resource type - Journals
eISSN - 1668-3501
pISSN - 0325-0075
DOI - 10.5546/aap.2021.e360
Subject(s) - medicine , ribavirin , asymptomatic , cirrhosis , adverse effect , sofosbuvir , hepatitis c virus , gastroenterology , virus , virology
Hepatitis C virus infection in children occurs mainly through vertical transmission. The natural history at this age consists in a high rate of spontaneous clearance, asymptomatic infection, or minimal histological changes. Disease complications are commonly seen in adolescence or adulthood. The classic treatment with pegylated interferon and ribavirin presents adverse effects, prolonged duration and achieves sustained viral response (SVR) in 50 % of patients with genotype 1 infection (the most frequent). New direct-acting antiviral treatments have been available in recent years for their indication from 12 years of age with excellent tolerance and a high SVR rate. Expectant therapeutic behavior is suggested in asymptomatic patients until they can access to them. We report the case of an adolescent with chronic hepatitis C without cirrhosis who received 12 weeks treatment with ledipasvir/sofosbuvir, achieving SVR.